GlassScriptPhysician profile
Derrick Meadow
NPI 1992338719
$34,246.21
in general payments reported to CMS, 2019-2025
21 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,894 · 2022: $6,203 · 2023: $1,738 · 2024: $14K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $5,356 · Travel and Lodging: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,420.00 |
| Food and Beverage | $5,355.76 |
| Travel and Lodging | $1,373.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22,455.29 | 2023-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $5,818.89 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $1,176.09 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,022.55 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $924.40 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $704.79 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $380.04 | 2021-2024 | Trintellix |
| Indivior INC. | $376.07 | 2021-2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $298.96 | 2021-2024 | Nuedexta, Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $277.95 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $230.00 | 2023-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $217.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $92.96 | 2021-2023 | Belsomra |
| Lundbeck LLC | $85.36 | 2021-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $38.74 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $32.69 | 2022 | |
| Axsome Therapeutics, INC. | $30.68 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $26.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.91 | 2021 | |
| Eisai INC. | $17.24 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Meadow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.